APAlan Premasiri

Alan Premasiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alan Premasiri has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The association between at-home exercise digital metrics and ALS disease progression in lower limbs

    by Marcin Straczkiewicz, Narghes Calcagno, Katherine M. Burke, Sravan Mandepudi, Horacio Sanchez Trigo, Alan Premasiri, Fernando G. Vieira, James D. Berry

    Background: Clinical assessments of Amyotrophic Lateral Sclerosis (ALS) are typically collected infrequently in clinic visits and may not fully capture domain-specific functional decline in daily life. Digital Health Technologies (DHTs) can support remote monitoring, but passive free-living measures often require prolonged wear time and may be influenced by non-motor factors. This study evaluated whether short, standardized, at-home lower limb exercises recorded with ankle-worn accelerometers provide objective and interpretable measures of lower limb disease progression in ALS. Methods: We analyzed data from 349 participants with ALS enrolled in the decentralized ALS Research Collaborative Study. Participants completed repeated self-entry ALS Functional Rating Scale-Revised (ALSFRS-RSE) assessments and wore bilateral ankle accelerometers during monitoring periods between September 2014 and January 2023. During each period, participants performed brief seated knee flexion-extension exercises at home. A previously developed signal processing pipeline was used to derive four exercise metrics: count, duration, intensity, and similarity. We examined baseline correlations with ALSFRS-RSE total and subdomain scores, longitudinal change using linear mixed-effects models, associations with gross motor item scores, differences by anatomical site of disease onset, and comparisons with free-living gait metrics. Results: At baseline, exercise-derived metrics, particularly intensity and similarity, showed the strongest associations with the gross motor subdomain. Longitudinally, duration increased while intensity and similarity decreased, consistent with progressive slowing, reduced movement vigor, and reduced movement consistency (all p < 0.001); count did not change significantly. Worsening responses to gross motor items related to turning in bed, walking, and stair climbing were consistently associated with fewer, slower, less vigorous, and less consistent lower limb repetitions. Baseline intensity and similarity were lower in participants with lower limb disease onset on the corresponding side. Exercise-derived intensity showed model fit comparable to the strongest free-living gait metrics, while requiring substantially less observation time. Conclusions: Short at-home lower limb exercises recorded using ankle-worn accelerometers provide scalable, objective, and interpretable measures of amyotrophic lateral sclerosis-related functional decline. Movement quality metrics, particularly intensity and similarity, may complement passive free-living monitoring and support remote digital clinical outcome assessment in ALS research. Trial registration: NCT06885918.

  • Open Access

    Quantifying longitudinal gait changes in ALS using wearable digital health technology metrics

    by Katherine M. Burke, Narghes Calcagno, Sravan Mandepudi, Alan Premasiri, Kendall C. Hall, Fernando G. Vieira, James D. Berry, Marcin Straczkiewicz

    Wearable digital health technologies may complement traditional gait assessments in amyotrophic lateral sclerosis (ALS) by sensitively capturing real-world mobility changes. In this study, we validated six digital gait metrics derived from ankle-worn sensors in a natural history cohort of 182 individuals with ALS. Investigated metrics correspond to various aspects of gait, including volume, speed, intensity, similarity, variability, and fragmentation. Longitudinal analyses showed significant declines in step count, peak cadence, stride intensity, and stride similarity, with increasing stride duration variability and walking fragmentation over 52 weeks. Many participants exhibited greater relative change in the gait metrics than the self-reported ALS Functional Rating Scale-Revised (ALSFRS-RSE). Stratified analyses revealed that digital metrics captured significant functional decline even in participants with stable walking scores on the ALSFRS-RSE. These findings support the potential utility of these metrics for disease monitoring in ALS clinical care and trials.


  • Open Access

    Analytical and clinical validation of step counting method in people living with amyotrophic lateral sclerosis

    by Marcin Straczkiewicz, Katherine M. Burke, Kendall T. Carney, Narghes Calcagno, Sravan Mandepudi, Alan Premasiri, Fernando G. Vieira, James D. Berry

    Background Accelerometer-based digital measures offer a scalable and low-burden means of quantifying physical function, but existing processing algorithms may not quantify pathological gait correctly. In people living with amyotrophic lateral sclerosis (ALS), where gait patterns are slow, variable, and asymmetric, validated tools to quantify mobility are urgently needed. Methods We proposed a step-counting algorithm designed for ankle-worn accelerometers that leverage wavelet-based decomposition to quantify heel strikes under heterogeneous gait patterns. We validated this method using five datasets comprised of healthy individuals and those with ALS in controlled and semi-controlled activities, and we performed clinical validation in a free-living cohort of 305 people with ALS. We tested our method for accuracy in detecting steps and recognizing walking activity. Reference labels used for analytical validation were obtained from annotated studies or video-based ground truth. Step counting accuracy was assessed using Bland-Altman analysis while clinical validity was evaluated by comparing step counts to gross motor functioning on the ALS Functional Rating Scale – Revised (ALSFRS-R). Results Walking recognition was robust across walking conditions and body types; sensitivity ranged from 0.94 to 0.98, and specificity exceeded 0.95 across all evaluated datasets. The mean step counting bias was minimal (e.g., 0.44 steps), and the 95% limits of agreement were narrow (LoA = [−5.90, 5.40]) relative to reference standards, including video-annotated ground truth. Clinical validation indicated substantial differences between groups with various levels of gait impairment, e.g., participants who reported “walks with assist” on the ALSFRS-R accumulated a mean of 1283 (95% CI: 1063, 1503) steps/day, while those reporting “normal” walking covered 3984 (95% CI: 3537, 4432) steps/day. Conclusions Our study covered analytical and clinical validation of a step-counting method developed for ankle-worn accelerometers and demonstrated its applicability to pathological gait. The method provides accurate quantification of walking activity in controlled and free-living environments, supporting its use as a digital endpoint in ALS research.

  • Open Access

    Short prescribed exercises can quantify upper limb functioning in neurodegenerative disease

    by Marcin Straczkiewicz, Katherine M. Burke, Narghes Calcagno, Alan Premasiri, Kendall T. Carney, Fernando G. Vieira, Jukka-Pekka Onnela, James D. Berry

    Digital health technologies (DHTs) can quantify movements in daily routines but rely heavily on participant adherence over prolonged wear times. Here we analyze accelerometry data from wrist-worn devices during short episodes of prescribed exercises (PEs) performed by 329 individuals living with amyotrophic lateral sclerosis (ALS) in a longitudinal study. We developed an automated and interpretable signal processing method to estimate upper limb movement counts, duration, intensity, and similarity of repetitions during PEs. Upper limb swing duration increased while intensity and similarity of movement decreased over time, indicating longer but less vigorous and less consistent upper limb movements over time. Intensity emerged as the most robust predictor of changes in upper limb function. The results suggest that PEs can effectively quantify upper limb function comparable to certain free-living measurements, providing greater flexibility in the clinical application of DHTs.

  • Open Access

    At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis

    by Anoopum S. Gupta, Siddharth Patel, Alan Premasiri, Fernando Vieira

    Amyotrophic lateral sclerosis causes degeneration of motor neurons, resulting in progressive muscle weakness and impairment in motor function. Promising drug development efforts have accelerated in amyotrophic lateral sclerosis, but are constrained by a lack of objective, sensitive, and accessible outcome measures. Here we investigate the use of wearable sensors, worn on four limbs at home during natural behavior, to quantify motor function and disease progression in 376 individuals with amyotrophic lateral sclerosis. We use an analysis approach that automatically detects and characterizes submovements from passively collected accelerometer data and produces a machine-learned severity score for each limb that is independent of clinical ratings. We show that this approach produces scores that progress faster than the gold standard Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (−0.86 ± 0.70 SD/year versus −0.73 ± 0.74 SD/year), resulting in smaller clinical trial sample size estimates (N = 76 versusN = 121). This method offers an ecologically valid and scalable measure for potential use in amyotrophic lateral sclerosis trials and clinical care.


  • Open Access

    A Machine-Learning Based Objective Measure for ALS Disease Severity

    by Fernando G. Vieira, Subhashini Venugopalan, Alan S. Premasiri, Maeve McNally, Aren Jansen, Kevin McCloskey, Michael P. Brenner, Steven Perrin

    Amyotrophic Lateral Sclerosis (ALS) disease severity is usually measured using the subjective, questionnaire-based revised ALS Functional Rating Scale (ALSFRS-R). An objective measure for tracking disease severity and progression would be a powerful tool for evaluating real-world drug effectiveness, efficacy in clinical trials, as well as identifying participants for cohort studies. Here we develop a machine learning (ML) based objective measure for ALS disease severity, based on voice samples and accelerometer measurements from a longitudinal dataset collected by the ALS Therapy Development Institute (ALS-TDI) over four years. 584 people living with ALS consented and carried out prescribed speaking and limb-based tasks. 542 participants contributed 5814 voice recordings, and 350 contributed 13009 accelerometer samples, while simultaneously measuring ALSFRS-R scores. Using the data from 475 participants, we trained machine learning (ML) models to predict bulbar-related FRS scores from speech, and limb-related scores from accelerometer samples. On the test set (n=109 participants) the voice models achieved a multiclass AUC of 0.86 (95% CI, 0.85-0.88) on speech FRS prediction, whereas the accelerometer models achieved a median multiclass AUC of 0.73 on 6 limb-related functions. Further, the correlation (and inverse correlations) across different bulbar and limb functions observed in the self-reported ALSFRS-R scores are preserved in the ML-derived scores. Next, we used these models and self-reported ALSFRS-R scores to evaluate the real-world effects of edaravone, a drug recently approved for use in ALS. In the cohort of 54 test participants who received edaravone as part of their usual care, the ML-derived objective scores were consistent with the self-reported ALSFRS-R scores, and both showed highly variable outcomes from edaravone treatment from person to person. At the individual level, the continuous ML-derived score is able to capture a gradual change that is absent in the integer ALSFRS-R scores. This demonstrates the value of these tools for assessing both disease severity and potentially drug effects.

  • Open Access

    Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity

    by Alan S. Premasiri, Anna L. Gill, Fernando G. Vieira

    Repeat expansion mutations in the C9ORF72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Repeat-associated non-AUG translation of this expansion produces dipeptide repeat proteins (DRPs). The arginine containing DRPs, polyGR and polyPR, are consistently reported to be the most toxic. Here we demonstrated that small molecule inhibition of type I protein arginine methyltransferases (PRMT) protects against polyGR and polyPR toxicity. Furthermore, our findings suggest that asymmetric dimethylation of polyGR and polyPR by Type I PRMTs plays important roles in their cytotoxicity.


  • Open Access

    Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity

    by Alan S. Premasiri, Anna L. Gill, Fernando G. Vieira

    The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a repeat expansion mutation in the C9orf72 gene. Repeat-associated non-AUG (RAN) translation of this expansion produces five species of dipeptide repeat proteins (DRPs). The arginine containing DRPs, polyGR and polyPR, are consistently reported to be the most toxic. Here, we uncover Type I protein arginine methyltransferase (PRMT) inhibitors as possible therapeutics for polyGR- and polyPR- related toxicity. Furthermore, we reveal data that suggest that asymmetric dimethylation (ADMe) of polyGR is a determining factor in its pathogenesis.


  • Open Access

    Primary Neurons and Differentiated NSC-34 Cells Are More Susceptible to Arginine-Rich ALS Dipeptide Repeat Protein-Associated Toxicity than Non-Differentiated NSC-34 and CHO Cells

    by Anna L. Gill, Monica Z. Wang, Beth Levine, Alan Premasiri, Fernando G. Vieira

    A repeat expansion mutation in the C9orf72 gene is the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In this study, using multiple cell-based assay systems, we reveal both increased dipeptide repeat protein (DRP) toxicity in primary neurons and in differentiated neuronal cell lines. Using flow cytometry and confocal laser scanning microscopy of cells treated with fluorescein isothiocyanate (FITC)-labeled DRPs, we confirm that poly-glycine-arginine (GR) and poly-proline-arginine (PR) DRPs entered cells more readily than poly-glycine-proline (GP) and poly-proline-alanine (PA) DRPs. Our findings suggest that the toxicity of C9-DRPs may be influenced by properties associated with differentiated and aging motor neurons. Further, our findings provide sensitive cell-based assay systems to test phenotypic rescue ability of potential interventions.